Overview
This study evaluates the representativeness and reliability of electronic health record (EHR)-derived oncology data from Germany, focusing on breast, lung, and colorectal cancer cohorts. By comparing these datasets to national benchmarks, the research validates their use in generating real-world evidence (RWE).
The study found that the demographic and clinical characteristics of these cohorts closely align with national cancer registry data. Additionally, the validation of mortality endpoints demonstrated high sensitivity and specificity, confirming the datasets' robustness for survival analysis. This alignment supports the use of these datasets for regulatory submissions and comparative-effectiveness research in Germany.
Why this matters
The availability of high-quality real-world data is crucial for advancing cancer research and healthcare decision-making. This study demonstrates that the Flatiron Health Germany EHR-derived datasets are representative and reliable, making them valuable resources for generating evidence that can inform clinical practice and policy. By providing a comprehensive view of cancer care in Germany, these datasets help bridge gaps in existing data, supporting more personalized and effective treatment strategies. This research underscores the potential of real-world evidence to enhance cancer care by providing insights that complement traditional clinical trials.